Jiang Tinghui, Li Mengfan, Li Qiuyin, Guo Zhiqiang, Sun Xianjun, Zhang Xufeng, Liu Yan, Yao Wenyi, Xiao Ping
Oncol Res. 2017 Aug 7;25(7):1117-1127. doi: 10.3727/096504016X14821952695683. Epub 2016 Dec 21.
Some microRNAs (miRs) have been demonstrated to play promoting or tumor-suppressing roles in the development and progression of hepatocellular carcinoma (HCC). However, the regulatory mechanism of miR-98-5p in HCC still remains largely unclear. In the present study, our data showed that miR-98-5p was significantly downregulated in 84 cases of HCC tissues compared to the matched adjacent nontumor tissues. In addition, downregulation of miR-98-5p was associated with tumor size, portal vein tumor embolus, node metastasis, and clinical stage in HCC. HCC patients with low expression of miR-98-5p showed a shorter survival time compared with those with high miR-98-5p levels. Moreover, the expression of miR-98-5p was also reduced in HCC cell lines (HepG2, Hep3B, LM3, and SMCC7721) compared to the normal liver cell line THLE-3. Overexpression of miR-98-5p significantly decreased LM3 cell growth by inducing cell cycle arrest at the G1 stage and cell apoptosis. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) was then identified as a novel target gene of miR-98-5p, and its protein expression was negatively regulated by miR-98-5p in LM3 cells. Overexpression of IGF2BP1 eliminated the effects of miR-98-5p overexpression on the proliferation, cell cycle, and apoptosis of LM3 cells. Finally, we found that IGF2BP1 was upregulated in HCC, and its expression was negatively correlated to miR-98-5p levels. In summary, we demonstrate that miR-98-5p could inhibit HCC cell proliferation while inducing cell apoptosis, partly at least, via inhibition of its target gene IGF2BP1, and we suggest that miR-98-5p may become a promising therapeutic candidate for HCC treatment.
一些微小RNA(miR)已被证明在肝细胞癌(HCC)的发生和发展中发挥促进或抑癌作用。然而,miR-98-5p在HCC中的调控机制仍不清楚。在本研究中,我们的数据显示,与配对的癌旁非肿瘤组织相比,84例HCC组织中miR-98-5p显著下调。此外,miR-98-5p的下调与HCC的肿瘤大小、门静脉癌栓、淋巴结转移及临床分期相关。miR-98-5p低表达的HCC患者与miR-98-5p高表达患者相比生存期更短。此外,与正常肝细胞系THLE-3相比,HCC细胞系(HepG2、Hep3B、LM3和SMCC7721)中miR-98-5p的表达也降低。miR-98-5p的过表达通过诱导细胞周期阻滞在G1期和细胞凋亡显著降低LM3细胞的生长。胰岛素样生长因子2 mRNA结合蛋白1(IGF2BP1)随后被鉴定为miR-98-5p的一个新靶基因,其蛋白表达在LM3细胞中受到miR-98-5p的负调控。IGF2BP1的过表达消除了miR-98-5p过表达对LM3细胞增殖、细胞周期和凋亡的影响。最后,我们发现IGF2BP1在HCC中上调,其表达与miR-98-5p水平呈负相关。总之,我们证明miR-98-5p可以抑制HCC细胞增殖并诱导细胞凋亡,至少部分是通过抑制其靶基因IGF2BP1实现的,并且我们认为miR-98-5p可能成为HCC治疗的一个有前景的治疗候选物。